KLRC1 and neoplasm: Since NK cell function in the brain is often impaired by hypoxia, adenosine, and inhibitory receptors, combinations such as IL-15 super-agonists, A2A receptor antagonists, and anti-NKG2A antibodies may help restore their anti-tumor activity.